Adia Nutrition Inc. Delivers Explosive Third Quarter Growth: Revenue Surges Over 100% from Prior Quarter, with Remarkable Profit Margin Exceeding 20%
Rhea-AI Summary
Adia Nutrition (OTCQB: ADIA) reported preliminary Q3 results for the quarter ended September 30, 2025 showing a revenue increase of more than 100% quarter‑over‑quarter and a profit margin exceeding 20%. Growth was attributed to higher sales of umbilical cord stem cells and exosome therapies across clinical partnerships, direct‑to‑consumer channels, and national expansion. Management described the quarter as a milestone for the company and said full reviewed financial statements will be posted on OTC Markets and filed by on or before November 15, 2025.
Contact and partnership inquiries directed to CEO Larry Powalisz.
Positive
- Revenue grew by >100% QoQ in Q3 2025
- Profit margin reported at >20% for the quarter
- Sales expansion across clinical, DTC, and national channels
Negative
- Results are preliminary and will be subject to review before the Nov 15, 2025 filing
News Market Reaction
On the day this news was published, ADIA gained 8.00%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Winter Park, Florida--(Newsfile Corp. - October 8, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a trailblazer in umbilical cord stem cells and exosome sales and therapies, today announced phenomenal preliminary financial results for the third quarter ended September 30, 2025. The company achieved a monumental revenue increase of more than
"This third quarter marks a historic leap forward for Adia Nutrition," said CEO Larry Powalisz. "Doubling our revenue in a single quarter while achieving such a robust profit margin is a powerful reflection of our team's dedication, our cutting-edge therapeutic portfolio, and the trust of our rapidly expanding customer base. We're not just growing, we're redefining what's possible in the regenerative medicine space."
Key highlights from the preliminary third quarter results include:
Revenue Surge: Revenue grew by over
100% from the second quarter, fueled by skyrocketing sales of umbilical cord stem cells and exosomes across clinical partnerships, direct-to-consumer channels, and national market expansion.Profit Triumph: A profit margin exceeding
20% , showcasing operational efficiency, strategic investments, and the strength of high-margin therapeutic offerings resonating with patients and healthcare providers.Unstoppable Momentum: These results build on Adia Nutrition's year-to-date success, positioning the company for record-breaking annual growth and enhanced shareholder value.
The full third quarter financial report, including reviewed statements and detailed metrics, will be released and posted on the OTC Markets website (www.otcmarkets.com) on or before November 15, 2025, and filed with the appropriate regulatory bodies.
For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-788-0850.
Clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating Adia's regenerative therapies into their practice are encouraged to reach out directly. Strategic partnerships are welcomed as part of Adia's continued mission to expand access to advanced stem cell solutions.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTCQB: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/269471
FAQ
What did Adia Nutrition (ADIA) report for Q3 2025 on October 8, 2025?
When will Adia Nutrition file the reviewed Q3 2025 financial statements for ADIA?
What drove the Q3 2025 revenue surge for ADIA?
How material is ADIA's reported profit margin in Q3 2025 for investors?
Are ADIA's Q3 2025 results final and audited?
How can investors or partners contact Adia Nutrition about Q3 results or licensing?
